Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment
Condition studied
Acute procedural pain associated with oocyte pick-up (oocyte retrieval) in women undergoing IVF/ART.
Investigational medicinal product(s)
Every trial of Sufentanil and Midazolam across our registers →
Eligibility
Primary endpoint
Overall intra-procedural pain intensity during OPU, VAS 0–100 mm recorded every 2 minutes from first puncture to completion; primary derived measure (mean/median or VAS-AUC over time) per SAP.
Endpoint detail
Patient satisfaction with pain management at ~24 h post-OPU using APS-POQ-R., Post-OPU VAS pain at T0 (arrival in recovery), 30 min, 1 h, and discharge., Rescue analgesic use at home within 24 h (type/amount)., Nausea/vomiting incidence: pre-OPU, immediate post-OPU, 30 min, 1 h, discharge, and at 24 h., Respiratory depression/other AEs during and immediately after OPU (SpO₂, RR, clinical observation)., Vaginal bleeding (usual/less/more than usual)., Recovery metrics: time to discharge, procedure duration, number of oocytes retrieved, operator experience level., Hormonal/fertility markers: E2/FSH/LH/progesterone and follicle count (2 days pre-OPU); HCG 2 weeks post-ET; clinical pregnancy at ~7 weeks.
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-523018-10-00 on CTIS ↗ ← All trials in the EU